



November 11, 2015

## **Intra-Cellular Therapies to Present at Jefferies Autumn 2015 Global Healthcare Conference in London**

NEW YORK, Nov. 11, 2015 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced it will participate in the Jefferies Autumn 2015 Global Healthcare Conference in London on Thursday, Nov. 19, 2015. Sharon Mates, Ph.D., Chief Executive Officer and Chairman, will present at 10:40 a.m. GMT.

The live and archived webcast can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at [www.intracellularthérapies.com](http://www.intracellularthérapies.com). Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.

### **About Intra-Cellular Therapies**

Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease. The Company is developing its lead drug candidate, ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in dementia, depression and other neuropsychiatric and neurological disorders. ITI-007, a first-in-class molecule, is in Phase 3 clinical development for the treatment of schizophrenia. The Company is also utilizing its phosphodiesterase platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders.

CONTACT: Juan Sanchez, M.D.

Vice President

Corporate Communications and Investor Relations of

Intra-Cellular Therapies, Inc.

Phone: 212-923-3344

Burns McClellan, Inc.

Lisa Burns

Justin Jackson (Media)

[jjackson@burnsmc.com](mailto:jjackson@burnsmc.com)

212-213-0006



Source: Intra-Cellular Therapies, Inc.

News Provided by Acquire Media